Tempus AI, Inc. - Class A Common Stock (NQ:TEM)

66.56 -1.05 (-1.55%)

Delayed Quote Updated: 2:22 PM EDT, Oct 26, 2026 Add to My Watchlist

Quote

Overview Detailed Quote Charting Historical Prices

News

All News News Headlines Press Releases

Research

Quarterly Reports Insider Filings Other Filings

All News about Tempus AI, Inc. - Class A Common Stock

< Previous 1 2 3 4 5 6 7 8 9

...

20 21 Next >

Tempus Receives IVDR Certification for xR RNA Sequencing for Solid Tumor Profiling

Today 8:30 EDT

From Tempus AI, Inc.

Via Business Wire

Tempus Expands Strategic Collaboration with Bristol Myers Squibb

October 23, 2026

From Tempus AI, Inc.

Via Business Wire

Pathos AI Announces Strategic Collaborations with Bristol Myers Squibb and Tempus AI to Advance AI-Driven Drug Development Beginning with Alzheimer’s Disease and Other Neurological Conditions

October 23, 2026

From Pathos AI

Via Business Wire

Tempus Presents Data Demonstrating AI-Enabled Pre-Screening Can Help Identify Patients for Biomarker Testing in NSCLC

October 19, 2026

From Tempus AI, Inc.

Via Business Wire

The AI Trade Just Moved Into Your Bloodstream, and 4 Healthcare Stocks Are Winning ↗

October 19, 2026

AI-driven "biointelligence" is reshaping healthcare investing, with Guardant Health, Illumina, Eli Lilly and Moderna emerging as key stocks as data-driven testing, sequencing and therapies compound.

Via MarketBeat

Topics Artificial Intelligence

Tempus to Report Third Quarter 2026 Financial Results on November 2

October 15, 2026

From Tempus AI, Inc.

Via Business Wire

The $1 Trillion AI Healthcare Revolution: A New Era of Medical Innovation Is Taking Shape

October 15, 2026

AI-powered diagnostics, drug discovery and intelligent medical technology are opening the door to a potentially massive global market projected to reach $1 trillion by 2034 New York, NY – October 15,...

Via FinancialNewsMedia

Topics Artificial Intelligence

The $1 Trillion AI Healthcare Revolution: A New Era of Medical Innovation Is Taking Shape

October 15, 2026

AI-powered diagnostics, drug discovery and intelligent medical technology are opening the door to a potentially massive global market projected to reach $1 trillion by 2034

From FN Media

Via GlobeNewswire

Ambry Genetics Announces GenomeNext™, a Whole Genome Sequencing Test Solution to Improve Diagnosis for Rare Diseases

October 13, 2026

From Ambry Genetics

Via Business Wire

Tempus Announces Multi-Year Collaboration with Moderna and Merck

October 07, 2026

From Tempus

Via Business Wire

Tempus Announces 13 Abstracts Accepted for Presentation at the European Society for Medical Oncology Congress 2026

October 01, 2026

From Tempus AI, Inc.

Via Business Wire

Tempus Receives FDA Clearance for its ECG-MR AI Product Designed to Identify Undiagnosed Mitral Regurgitation

September 28, 2026

From Tempus AI, Inc.

Via Business Wire

Tempus AI Chief Accounting Officer Sells $529,650 of Stock ↗

September 24, 2026

Sale follows 30% rebound in the stock year to date.

Via The Motley Fool

Topics Artificial Intelligence Regulatory Compliance

Tempus AI Sees Pricing, Data Growth Fueling Long-Term Expansion ↗

September 21, 2026

Tempus AI (NASDAQ:TEM) Founder and CEO Eric Lefkofsky said the company’s second-quarter performance was supported by continued demand for comprehensive genomic profiling and growth in its...

Via MarketBeat

Topics Artificial Intelligence

Tempus and Recursion Extend Existing Data License Agreement and Enter New License Agreement for Recursion’s RNA Foundation Model

September 21, 2026

From Tempus AI, Inc.

Via Business Wire

Tempus Launches Effort to Build the Largest Multimodal Whole-Genome Dataset to Advance AI-Driven Healthcare Innovation

September 11, 2026

From Tempus AI, Inc.

Via Business Wire

Tempus Secures Up to $9.5 Million in ARPA-H ADVOCATE Funding to Deploy First Autonomous AI in Cardiology

September 09, 2026

From Tempus AI, Inc.

Via Business Wire

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Personalis, Inc. (Nasdaq – PSNL), Werewolf Therapeutics, Inc. (Nasdaq – HOWL), Beazer Homes USA, Inc. (NYSE – BZH), MarketAxess Holdings Inc. (Nasdaq – MKTX)

September 09, 2026

From Brodsky & Smith LLC

Via GlobeNewswire

Tempus to Participate in the Morgan Stanley 24th Annual Global Healthcare Conference

September 04, 2026

From Tempus AI, Inc.

Via Business Wire

September 03, 2026

From Brodsky & Smith LLC

Via GlobeNewswire

Tempus AI Director Nadja West Sells 3,000 Shares for $207,000 ↗

September 02, 2026

Sale executed under pre-established Rule 10b5-1 trading plan adopted in May, leaving West with 31,981 shares and a 0.0183% ownership stake.

Via The Motley Fool

Topics Artificial Intelligence Regulatory Compliance

Cathie Wood Invested Roughly $1.4 Billion of Ark Invest's Flagship ETF in Just 3 Artificial Intelligence (AI) Stocks ↗

August 28, 2026

Wood is known for being a tech-first investor.

Via The Motley Fool

Topics Artificial Intelligence ETFs Earnings

Tempus Receives FDA Clearance for its AI Product Intended to Detect Signs of Pulmonary Hypertension From Standard ECGs

August 24, 2026

From Tempus AI, Inc.

Via Business Wire

Why Tempus AI Skyrocketed This Week ↗

August 23, 2026

Tempus AI's latest acquisition is looking like a great move.

Via The Motley Fool

Topics Artificial Intelligence Stocks

A Tempus AI Director Sold Stock Four Days Before a 24% Rally. Here's What to Know ↗

August 22, 2026

West executed a sale under a pre-established Rule 10b5-1 trading plan, reducing her direct stake by 8% while retaining 34,981 shares worth roughly $1.8 million.

Via The Motley Fool

Topics Artificial Intelligence Regulatory Compliance

Is Tempus AI Stock a Buy After Its 75% Rally? Here's What to Know as the Firm's Legal Chief Files a Trade ↗

August 22, 2026

Polovin's sale of 30,075 shares was non-discretionary and tied to tax withholding from RSU vesting.

Via The Motley Fool

Topics Artificial Intelligence Regulatory Compliance

Tempus AI's Accounting Chief Just Reported an Insider Transaction. Here's What Long-Term Investors Should Know ↗

August 22, 2026

Bartolucci disposed of shares valued at $306,342 to cover statutory withholding obligations tied to RSU vesting, retaining direct holdings of 67,866 shares worth $3.35 million.

Via The Motley Fool

Topics Artificial Intelligence Regulatory Compliance

What to Know About the CFO of Tempus AI's Latest Insider Transaction Filing ↗

August 22, 2026

This non-discretionary sale to cover RSU withholding obligations reduced his direct stake, but he retains about 106,000 shares valued at $6.49 million.

Via The Motley Fool

Topics Artificial Intelligence Regulatory Compliance

Tempus AI's Diagnostics Chief Filed Stock Sales Spanning a Volatile Week. Here's What Happened ↗

August 22, 2026

These sales were driven by tax withholding obligations tied to restricted stock unit vesting under a pre-established trading plan.

Via The Motley Fool

Topics Artificial Intelligence Regulatory Compliance

Tempus AI's Data Chief Just Filed a Form 4. His Segment Grew 28% Last Quarter. ↗

August 22, 2026

This sale was non-discretionary, executed to cover tax withholding from RSU vesting.

Via The Motley Fool

Topics Artificial Intelligence Regulatory Compliance

< Previous 1 2 3 4 5 6 7 8 9

...

20 21 Next >

Stock Quote API & Stock News API supplied by www.cloudquote.io. Quotes delayed at least 20 minutes. Market data may be delayed. Research information, not personalized advice.